(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 August 2014 (21.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/127139 A1

(51) International Patent Classification:
A61K 31/47 (2006.01) *A61P 25/00* (2006.01)
A61K 31/197 (2006.01)

(21) International Application Number:
PCT/US2014/016278

(22) International Filing Date:
13 February 2014 (13.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/765,394 15 February 2013 (15.02.2013) US
61/911,106 3 December 2013 (03.12.2013) US

(71) Applicant *(for all designated States except US)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tikva (IL).

(72) Inventors; and
(71) Applicants *(for US only)*: **TARCIC, Nora** [IL/IL]; Migdal David 29/1, Modiin (IL). **BAR-ZOHAR, Dan** [IL/CH]; 13 Husslimattstrasse, CH-4132 Muttenz (CH). **HAYARDENY, Liat** [IL/IL]; 37 Yehuda Hanasie St., 69391 Tel Aviv (IL). **GILGUN SHERKI, Yossi** [IL/IL]; Hinnait 17, 42842 Bat Hefer (IL). **GORFINE, Tali** [IL/IL]; Shtrok 10, Tel-aviv (IL). **KNAPPERTZ, Volker** [US/US]; 8552 Brickyard Road, Potomac, MD 20854 (US). **SORANI, Ella** [IL/IL]; No. 2 Hakinor St., 6092000 Kadima (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD

Figure 1 of 1



(57) Abstract: This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.

WO 2014/127139 A1

Published:

— *with international search report (Art. 21(3))*